Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopenia
Described herein are systems and methods for treating, inhibiting, or ameliorating X-linked disorders including Wiskott-Aldrich Syndrome (WAS) and X-linked thrombocytopenia (XLT) in subjects that have been identified or selected as being ones that would benefit from a therapy to treat, inhibit, or ameliorate WAS or XLT. The systems include nuclease and vector donor constructs configured for co-delivery to modify endogenous WAS locus.
1. A system for promoting homology directed repair (HDR) of a Wiskott-Aldrich Syndrome (WAS) gene in a cell, the system comprising:
(i) a vector comprising:
a first polynucleotide encoding a WAS gene or portion thereof,
a second polynucleotide encoding a guide RNA cleavage site or a transcription activator-like effector nuclease (TALEN) cleavage site, and
a third polynucleotide encoding a nuclease binding site;
(ii) a nuclease or a nucleic acid encoding the nuclease, wherein the nuclease is capable of cleaving a target locus in order to promote insertion of the first polynucleotide within a first coding exon of the WAS gene in the cell genome, wherein the nuclease is selected from a transcription activator-like effector nuclease (TALEN), or a Cas nuclease; and
(iii) a guide RNA (gRNA) comprising a nucleotide sequence selected from any one of SEQ ID NOs:31-34.
2. The system of claim 1 , wherein the second polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO:17.
3. The system of claim 1 , wherein the vector further comprises an enhancer element, or a promoter.
4. The system of claim 1 , wherein the vector is an adeno-associated viral vector (AAV).
5. The system of claim 4 , wherein the vector is a self-complementary AAV (scAAV).
6. The system of claim 1 , wherein a cell comprises the vector and the nuclease.
7. The system of claim 6 , wherein the cell is a T cell or a hematopoietic stem cell (HSC).
8. The system of claim 7 , wherein the cell is a CD34 + HSC.
9. A pharmaceutical composition comprising the system of claim 6 and a pharmaceutically acceptable excipient.
10. The system of claim 1 , wherein the nuclease is a Cas nuclease.
11. The system of claim 1 , wherein the gRNA comprises the nucleotide sequence of SEQ ID NO:31.
12. The system of claim 1 , wherein the nuclease comprises a TALEN.
13. The system of claim 12 , the nucleic acid encoding a nuclease comprises a nucleotide sequence selected from any one of SEQ ID NOs: 27-30.
14. The system of claim 1 , wherein the vector comprises a sequence having at least 95% sequence identity with the nucleotide sequence set forth in SEQ ID NO:26.
15. The system of claim 14 , wherein the vector comprises the nucleotide sequence set forth in SEQ ID NO:26.
16. The system of claim 1 , wherein the vector and the nuclease or the nucleic acid encoding the nuclease are configured for co-delivery to a cell.
17. The system of claim 1 , wherein the WAS gene or portion thereof is a WAS cDNA codon-optimized for expression in a human gene.